Compugen signs development deal with Bayer; shares soar

Compugen (CGEN +58%) rockets higher after signing a deal with Bayer HealthCare (BAYZF.PK) for two projects to develop antibody-based immunotherapies for cancer

Under the deal, Bayer will get worldwide commercialization rights for any treatments that are produced.

Compugen will receive $10M upfront and over $530M in milestones, as well as mid-high single-digit royalties on sales of any products.

Antibody-based immunotherapies are designed to stimulate the body's immune cells to fight cancer. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs